Drug giant, Sun Pharma, got approval from USÂ Food and Drug Administration (USFDA) for an anti-psychotic drug Invega Generic or Palperidone.
The market size of this drug is around $300 million with two to three players already in the market.
Analysts says the company could make $25-30 million from this drug adding Rs 0.50 to the EPS in FY19.